Last updated on December 2018

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer


Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.